ReviewClinical microbiology reviews2024
Advancements and challenges in antifungal therapeutic development.
Review in Clinical microbiology reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Development Framework of Desirability of Outcome Ranking Endpoints for Use in Clinical Trials of Invasive Fungal Diseases.Open forum infectious diseases · 2026Trial
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- The Structure, Biosynthesis, and Function of β-1,6-Glucan in the Fungal Cell Wall.Biomolecules · 2026Review
- Epigenetic regulation of metabolism in Saccharomyces cerevisiae: mechanisms, metabolic crosstalk, and engineering applications.Molecular biology reports · 2026Review
- Integrative computational-experimental discovery of α-hederin as a multi-mechanistic, low-toxicity antifungal agent targeting Candida albicans CYP51.Journal of advanced research · 2026Article
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Synergistic Effects of Cepharanthine and Amphotericin B Against Candida albicans by Targeting PMP3-Mediated Sphingolipid Biosynthesis and Membrane Disruption.Mycopathologia · 2026Article
- Article
- The penta-EF-hand protein Pef1 of Candida albicans functions at sites of membrane perturbation to support polarized growth and membrane integrity.G3 (Bethesda, Md.) · 2026Article
- Screening the γ-core Motif Peptides of Ascomycetous Antifungal Proteins for Antifungal Activity and Potential Therapeutic Applicability.Probiotics and antimicrobial proteins · 2026Article
- Multifunctional Roles of Autophagy in Fungi.Journal of fungi (Basel, Switzerland) · 2026Review
- Ethanolic extract of Polish Propolis exhibits synergy with selected antifungal agents against yeast pathogens causing candidiasis.Scientific reports · 2026Article
- Mutational landscape and molecular bases of echinocandin resistance in Saccharomyces cerevisiae.Genetics · 2026Article
- Structural basis for transport and inhibition of nucleotide sugar transport in pathogenic fungi.Nature communications · 2026Article
- Evidence that increased azole persistence and stress resistance precede theMicrobiology spectrum · 2026Article
- An Antifungal with a Novel Mechanism of Action Discovered via Resistance Gene-Guided Genome Mining.ACS central science · 2026Article
- Glycolysis-dependent sulfur metabolism orchestrates morphological plasticity and virulence in fungi.eLife · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Over recent decades, the global burden of fungal disease has expanded dramatically. It is estimated that fungal disease kills approximately 1.5 million individuals annually; however, the true worldwide burden of fungal infection is thought to be higher due to existing gaps in diagnostics and clinical understanding of mycotic disease. The development of resistance to antifungals across diverse pathogenic fungal genera is an increasingly common and devastating phenomenon due to the dearth of available antifungal classes. These factors necessitate a coordinated response by researchers, clinicians, public health agencies, and the pharmaceutical industry to develop new antifungal strategies, as the burden of fungal disease continues to grow. This review provides a comprehensive overview of the new antifungal therapeutics currently in clinical trials, highlighting their spectra of activity and progress toward clinical implementation. We also profile up-and-coming intracellular proteins and pathways primed for the development of novel antifungals targeting their activity. Ultimately, we aim to emphasize the importance of increased investment into antifungal therapeutics in the current continually evolving landscape of infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.